Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8062 in fibromyalgia
NCT03092726Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in fibromyalgia (FM) comparing ASP8062 with Placebo (2 arms). Primary endpoints: Change From Baseline to Week 8 in Mean Daily Average Pain Score as Assessed by Numerical Rating Scale, Treatment-Emergent Adverse Events up to 87 days and 2 more. Started May 2017; status: completed.
02
Drugs
ASP8062
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT03092726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092726.